Document:

<PAGE>

                                                                   EXHIBIT 10.16

                                                                  EXECUTION COPY

                     AMENDED AND RESTATED LICENSE AGREEMENT

            This Amended and Restated License Agreement (this "Agreement") is
made effective as of May 20, 2004 (the "Restated Effective Date") by and between
Ramot at Tel Aviv University Ltd., Company Registration No. 51-066714-0, a
corporation duly organized and existing under the laws of the State of Israel
("Ramot") and Predix Pharmaceuticals Holdings, Inc. a corporation duly organized
and existing under the laws of the State of Delaware (hereinafter
"Predix")(Ramot and Predix are each hereafter referred to individually as a
"Party" and together as the "Parties").

      WHEREAS, Ramot is a company formed by Tel-Aviv University ("TAU") for
applied research and industrial development of know-how and inventions developed
or arrived at by scientists of TAU; and

      WHEREAS, by operation of law or under the terms of such scientists'
employment or other relationships with TAU or Ramot, and according to agreement
between TAU and Ramot, all rights, title and interest in and to such know-how
and inventions are owned by Ramot; and

      WHEREAS, Ramot has the right and authority to enter into agreements
relating to such know-how and inventions; and

      WHEREAS, Ramot (formerly Ramot University Authority For Applied Research
and Industrial Development Ltd.) and Predix (by assignment from a predecessor
corporation) are Parties to that certain License Agreement dated September 18,
2000 (the "Effective Date"), pursuant to which Ramot granted to Predix an
exclusive license under intellectual property rights controlled by Ramot and
pertaining to certain drug discovery and development technology (the "Original
Agreement"); and

      WHEREAS, Ramot and Predix now desire to amend and restate the Original
Agreement in its entirety as set forth herein.

      NOW, THEREFORE, in consideration of the mutual covenants contained herein,
and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties hereby agree as follows:

      1. DEFINITIONS

      Whenever used in the Agreement with an initial capital letter, the terms
defined in this Article 1 shall have the meanings specified.

            1.1 "AFFILIATE" shall mean, with respect to either Party, any other
person, corporation, company, partnership, joint venture and/or firm which
controls, is controlled by or is under common control with such Party. As used
in this Section 1.1 only, "control" of another person, corporation, company,
partnership, joint venture and/or firm shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the activities,
management or policies of such person, organization or entity, whether through
the ownership of voting securities, by contract or otherwise. Without limiting
the foregoing, control shall be presumed to

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

<PAGE>

exist when a person, corporation, company, partnership, joint venture and/or
firm (a) in the case of corporate entities, directly or indirectly owns at least
twenty percent (20%) of the stock or shares having the right to vote for the
election of directors, and (b) in the case of non-corporate entities, holds the
direct or indirect power to manage, direct or cause the direction of the
management and policies of the non-corporate entity or the power to elect at
least twenty percent (20%) of the members of the governing body of such
non-corporate entity, any corporation, firm, limited liability company,
partnership or other entity that directly controls or is controlled by or is
under common control with a Party to this Agreement.

            1.2 "CONFIDENTIAL INFORMATION" shall mean any confidential
scientific, technical, trade or business information relating to the subject
matter of this Agreement disclosed by or on behalf of one party to the other
that is either marked as confidential or if disclosed orally is reduced to a
written summary marked as confidential and delivered to the receiving party
within 30 days of disclosure. Confidential Information does not include
information that (i) is in possession of the receiving Party at the time of
disclosure, as reasonably demonstrated by written records; (ii) is or later
becomes part of the public domain through no fault of the receiving Party; (iii)
is received by a receiving Party from a third Party having no obligation of
confidentiality to the disclosing Party; or (iv) is developed independently by a
receiving Party without use of the disclosing Party's Confidential Information.

            1.3 "CONTROL" or "CONTROLLED" shall mean, with respect to any
intellectual property rights, the right and authority of a Party to grant the
rights, licenses and options provided for herein without breaching any written
agreement with any third Party by virtue of such grant.

            1.4 "DEVELOPMENT" and "DEVELOP" shall mean, with respect to any
Licensed Product, all activities with respect to such Licensed Product relating
to research and development and in connection with seeking, obtaining and/or
maintaining any Regulatory Approval for such Licensed Product in the Field in
the Territory, including without limitation, all pre-clinical research and
development activities, all human clinical studies, all activities relating to
developing the ability to manufacture any Licensed Product or any component
thereof (including, without limitation, process development work), and all other
activities relating to seeking, obtaining and/or maintaining any Regulatory
Approvals from the FDA and/or any Foreign Regulatory Authority.

            1.5 "DERIVATIVE WORK" means any software that is derived from the
Licensed Technology, including without limitation, software that is a
translation (including any translation into other computer languages),
portation, modification, correction, extension, upgrade, improvement,
compilation, abridgment, adaptation or other form of the Licensed Technology.
Derivative Works shall include without limitation any software that would
infringe any of Ramot's copyrights in the Licensed Technology.

            1.6 "DERIVED PRODUCT" shall mean a product, compound or drug
candidate that is identified, characterized or developed through the Use of
Licensed Technology and/or a Derivative Work, which is not a Discovered Product,
and that is commercialized by Predix, an Affiliate of Predix or a Sublicensee.
"Derived Products" include, without limitation, those compounds listed on
Exhibit 1.6 attached hereto.

            1.7 "DISCOVERED PRODUCT" shall mean a product, compound or drug
candidate that is identified from an in silico library through the Use of the
Licensed Technology and/or a

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       2
<PAGE>

Derivative Work, which is commercialized by Predix, an Affiliate of Predix or
a Sublicensee, without Modification and which had not been Modified by Predix
prior to such identification. For purposes of this Section 1.7, "Modification"
and "Modified" shall mean modification or optimization that increases the
likelihood that the product, compound or drug candidate can be successfully
developed into a drug product, including without limitation, by making
modifications to such product, compound or drug candidate to alter the
pharmacokinetics, bioavailability, toxicity, or efficacy, to improve stability,
to solve or avoid manufacturing issues or to avoid the intellectual property
rights of a Third Party.

            1.8 "DISPUTE" shall have the definition set forth in Section 10.1.

            1.9 "DRUG APPROVAL APPLICATION" shall mean any application for
Regulatory Approval (including pricing and reimbursement approvals) required
prior to any commercial sale or use of a Licensed Product in any country or
jurisdiction in the Territory.

            1.10 "FIELD" shall mean and include all uses, including without
limitation, all uses relating to the diagnosis, prevention and treatment of any
and all diseases or conditions in humans or animals.

            1.11 "FIRST COMMERCIAL SALE" shall mean, on a country-by-country
basis, the date of the first arm's length transaction, transfer or disposition
for value to a Third Party of a Licensed Product by or on behalf of Predix or
any Affiliate of Predix in such country after Regulatory Approval has been
achieved in the country in which such Licensed Product is sold. Sales for test
marketing, sampling and promotional uses, clinical trial purposes or
compassionate or similar use shall not be considered to constitute a First
Commercial Sale.

            1.12 "FDA" shall mean the United States Food and Drug Administration
and any successor agency or authority thereto.

            1.13 "FOREIGN REGULATORY AUTHORITIES" shall mean any applicable
supranational, national, federal, state or local regulatory agency, department,
bureau or other governmental entity of any country or jurisdiction in the
Territory (other than the FDA in the United States), having responsibility in
such country or jurisdiction for any Regulatory Approvals of any kind in such
country or jurisdiction, and any successor agency or authority thereto.

            1.14 "LICENSED PATENT RIGHTS" shall mean all Patent Rights owned by
Ramot that claim Licensed Technology.

            1.15 "LICENSED PRODUCT" shall mean any and all Derived Products and
Discovered Products, taken collectively.

            1.16 "LICENSED TECHNOLOGY" shall mean: (a) the inventions disclosed
in Israeli Patent Application IL 137885, including without limitation, the novel
computational method for modeling the three (3) dimensional structure of
G-protein coupled receptors from their one (1) dimensional sequence, (b) the
inventions disclosed in Israeli Patent Application IL 137886, including without
limitation, the novel automated protein design algorithm based on the physical
properties that determine the protein structure stability and that is useful for
predicting protein sequences likely to achieve a desired folding pattern in a
very high computational efficiency.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       3
<PAGE>

            1.17 "LICENSED TECHNOLOGY EXCLUSIVITY TERM" shall mean that period
commencing on the Effective Date and continuing until the later of: (a) the
expiration or termination of the last [************] within the Licensed Patent
Rights and (b) the [*******] anniversary of the Effective Date.

            1.18 "NET SALES" shall mean the gross invoiced sales price for all
Licensed Products sold by Predix and its Affiliates to Third Parties throughout
the Territory during each calendar quarter, less the following amounts incurred
or paid by Predix or its Affiliates during such calendar quarter with respect to
sales of Licensed Products regardless of the calendar quarter in which such
sales were made:

            (a) trade, cash and quantity discounts or rebates actually allowed
            or taken, including discounts or rebates to governmental or managed
            care organizations;

            (b) credits or allowances actually given or made for rejection of,
            and for uncollectible amounts on, or return of previously sold
            Licensed Products (including Medicare and similar types of rebates);

            (c) any charges for insurance, freight, and other transportation
            costs directly related to the delivery of Licensed Product to the
            extent included in the gross invoiced sales price;

            (d) any tax, tariff, duty or governmental charge levied on the
            sales, transfer, transportation or delivery of a Licensed Product
            (including any tax such as a value added or similar tax or
            government charge) borne by the seller thereof, other than franchise
            or income tax of any kind whatsoever; and

            (e) any import or export duties or their equivalent borne by the
            seller;

            provided that:

            (i) In any transfers of Licensed Products between Predix and an
Affiliate of Predix or between an Affiliate of Predix and an Affiliate of such
Affiliate, Net Sales (subject to the deductions listed above) shall be equal to
the higher of: (x) the [**************] of the Licensed Products so transferred,
assuming [********************************************************] and (y) the
total amount invoiced by such Affiliate on resale to an independent third party
purchaser; and

            (ii) In the event that Predix, or an Affiliate of Predix, receives
non-monetary consideration for any Licensed Products or in the case of
transactions not at arm's length with a non-Affiliate of Predix or its
Affiliate, Net Sales (subject to the deductions listed above) shall be
calculated based on the fair market value of such consideration or transaction,
assuming an arm's length transaction made in the ordinary course of business.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       4
<PAGE>

Notwithstanding the foregoing, "Net Sales" shall not include sales or transfers
between Predix and its Affiliates, if the Licensed Product is resold by the
Affiliate.

In the event that a Licensed Product under this Agreement is sold in combination
with another active ingredient or component having independent therapeutic
effect or diagnostic utility, then "Net Sales," for purposes of determining
royalty payments on the combination, shall be calculated by [******************
******************************************************************************
***********]. 1.19 "PATENT RIGHTS" shall mean all patent applications and
patents, including Israeli and foreign applications, divisions, continuations,
and continuations-in-part, applications for certificates of invention and
priority rights, certificates of invention, reissues, re-examination
certificates, extensions or other governmental acts that effectively extend the
period of exclusivity by the patent holder, substitutions, renewals,
supplementary protection certificates, confirmations, registrations, validations
and additions.

            1.20 "REGULATORY APPROVAL" shall mean any and all final approvals
(including pricing and reimbursement approvals), product and establishment
licenses, registrations or authorizations of any kind of the FDA or any Foreign
Regulatory Authority permitting the commercial sale of a Licensed Product (or
any component thereof) for use in the Field in any country or other jurisdiction
in the Territory.

            1.21 "ROYALTY TERM" shall mean with respect to each Licensed
Product, on a country-by-country basis, a period of twelve (12) years commencing
on the First Commercial Sale of such Licensed Product in such country.

            1.22 "SERVICE INCOME" shall mean all amounts and other consideration
received by Predix, or an Affiliate of Predix, for or in connection with the
performance of Services; provided that in the event that Predix or an Affiliate
of Predix receives non-monetary consideration in connection with any such
services or in the case of transactions not at arm's length, Service Income
shall be calculated based on the fair market value of such consideration or
transaction, assuming an arm's length transaction made in the ordinary course of
business.

            1.23 "SERVICES" shall mean services performed by Predix, or an
Affiliate of Predix, for the benefit of (a) a Third Party or (b) for the benefit
of a Third Party and Predix and/or an Affiliate of Predix, using the Licensed
Technology.

            1.24 "SOFTWARE PRODUCT" shall mean a software product that
incorporates Licensed Technology. Notwithstanding the foregoing, Software
Products that are also within the definition of "Discovered Product" or "Derived
Product" are hereby deemed to be Software Products only.

            1.25 "SUBLICENSE" shall mean a sublicense, assignment or other grant
of rights by Predix or an Affiliate of Predix to a Third Party (regardless of
whether such grant of rights is or is referred to as a sublicense) of or with
respect to: (a) some or all of the rights granted to Predix under this
Agreement; (b) a Software Product; or (c) the right to Develop, have Developed,
make, have made, use, have used, sell, offer for sale, have sold, import or have

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                        5
<PAGE>

imported Licensed Product(s). For avoidance of doubt, an assignment completed in
accordance with Section 11.3 shall not be included within the term "Sublicense".

            1.26 "SUBLICENSE INCOME" shall mean all amounts and other
consideration received by Predix or an Affiliate of Predix, in connection with a
Sublicense, excluding loans given at prevailing market conditions, research
funding specifically committed to cover costs [******] incurred by Predix in the
research and development of Licensed Products under and in accordance with
[**********************************] bona-fide sublicense agreements with
Sublicensees [*************************************************************
*******] and equity investments in Predix [**********************************];
provided that in the event that Predix or an Affiliate of Predix receives
non-monetary consideration in connection with any such Sublicense or in the case
of transactions not at arm's length, Sublicense Income shall be calculated based
on the fair market value of such consideration or transaction, assuming an arm's
length transaction made in the ordinary course of business. [*******************
*****************************************************************************].

            1.27 "SUBLICENSEE" shall mean any Third Party to whom Predix grants
a Sublicense.

            1.28 "TECHNOLOGY" shall mean any and all technical data,
information, processes, designs, ideas, know-how, methods, procedures, trade
secrets, formulae and all other technology, whether tangible or intangible and
whether patented, patentable or otherwise.

            1.29 "TERM" shall have the definition set forth in Section 9.1.

            1.30 "TERRITORY" shall mean all countries and jurisdictions of the
world.

            1.31 "THIRD PARTY" shall mean any person or entity other than
Predix, Ramot and their respective Affiliates.

            1.32 "USE" shall mean the use of the Licensed Technology or a
Derivative Work in any stage of the characterization, optimization or
development of a Licensed Product or the characterization of the protein
targeted by the Licensed Product; provided that such use either was made prior
to the Effective Date or is made during the Licensed Technology Exclusivity
Term.

            1.33 "VALID CLAIM" shall mean a claim in an unexpired patent or
patent application that: (a) has not been finally cancelled, withdrawn,
abandoned or rejected by any administrative agency or other body of competent
jurisdiction in a final non-appealable or unappealable decision, and (b) has not
been revoked, held invalid, or declared unpatentable in a decision of a court or
other body of competent jurisdiction that is unappealable or unappealed within
the time allowed for appeal.

      2. GRANT OF RIGHTS

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                        6
<PAGE>

      2.1 LICENSE TO PREDIX.

            2.1.1 Grant of License. Ramot hereby grants to Predix an exclusive,
royalty-bearing license, including the right to grant sublicenses in accordance
with Section 2.1.2, under the Licensed Patent Rights and Licensed Technology,
during the Term, to Develop, have Developed, make, have made, use, have used,
sell, offer for sale, have sold, import and have imported, Licensed Products in
the Territory, for any and all uses within the Field, subject to the terms and
conditions of this Agreement.

            2.1.2 Right to Sublicense. Predix shall have the right to grant
sublicenses to any Sublicensee to all or any portion of its rights under the
license granted pursuant to this Article 2, including without limitation as part
of a license to a Software Product; provided, however, that any and all such
sublicenses shall be made for consideration and in arm's length transactions.
Predix shall promptly deliver to Ramot a copy of all sublicenses and all
sublicenses shall be consistent with the material terms and conditions of this
Agreement that impact Ramot.

      3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS.

            3.1 COMMERCIALIZATION.

                  3.1.1 Responsibility. From and after the Effective Date,
Predix shall have full control and authority over the Development and
commercialization of Licensed Products. All activities relating to Development
and commercialization under this Agreement shall be undertaken at Predix's sole
cost and expense.

                  3.1.2 Diligence. Predix will exercise [***********************
********] in developing and commercializing Licensed Products in the Field in
the Territory, such [*********************] to be in accordance [************
*****************************************************************************].
The collective annual expenditure by Predix, its Affiliates and Sublicensees of
not less than [*******************************] on the Development of Licensed
Products shall be deemed to satisfy Predix's obligations under this Section
3.1.2 for such year.

      4. PAYMENTS AND ROYALTIES

            4.1 LICENSE FEE. In consideration of the grant of the license
described in Section 2.1 hereof, Predix agrees to the payment to Ramot of an
upfront license fee in the amount of forty thousand dollars ($40,000). Ramot
hereby acknowledges the receipt of such payment prior to the Restated Effective
Date.

            4.2 SHARING OF SUBLICENSE INCOME. In further consideration of the
grant of the license by Ramot hereunder, and subject to the other terms of this
Agreement (including the remainder of this Article 4), Predix agrees to pay to
Ramot, within [***********] of receipt of

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       7
<PAGE>

any Sublicense Income, an amount equal to: (a) ten percent (10%) of such
Sublicense Income if such Sublicense Income is attributable to a Sublicense
with respect to Discovered Products or Software Products and (b) five percent
(5%) of any and all other Sublicense Income.

            4.3 SERVICE INCOME. In further consideration of the grant of the
license by Ramot hereunder, and subject to the other terms of this Agreement
(including the remainder of this Article 4), Predix agrees to pay to Ramot,
within [***********] of receipt of any Service Income, an amount equal to: (a)
[**] of all cumulative Service Income from [*********] to [*****************];
(b) [**] of all cumulative Service Income from [*********] to [************];
and (c) an amount equal to [**] of all cumulative Service Income above [****
*******]. Predix shall not be required to pay Ramot any amount on the first
[********] in cumulative Service Income.

            4.4 PAYMENT OF ROYALTIES; ROYALTY RATES; MINIMUM AND MAXIMUM ANNUAL
ROYALTIES.

                  4.4.1 Royalty Payments In further consideration of the grant
of the  license by Ramot hereunder, and subject to the other terms of this
Agreement (including the remainder of this Article 4), commencing on the date
of the First Commercial Sale of each Licensed Product and continuing during the
Royalty Term for such Licensed Product, Predix shall pay to Ramot a royalty,
calculated on a Licensed Product-by-Licensed Product basis, and equal to a
percentage of cumulative annual Net Sales of each such Licensed Product sold by
Predix and/or its Affiliates in the Territory, as set forth below:

<TABLE>
<CAPTION>
                                                       PERCENTAGE OF NET SALES
LICENSED PRODUCT TYPE     ANNUAL NET SALES              PAYABLE AS ROYALTY
---------------------     -----------------            ----------------------
<S>                       <C>                          <C>
Discovered Products       [***************]                       2.5%

                          [***************]                      [***]
                          [********]

                          [***************]                      [***]

Derived Products          [***************]                       1.5%

                          [***************]                      [***]
                          [********]

                          [***************]                      [***]
</TABLE>

                  4.4.2 Minimum Royalties. In further consideration of the grant
of the license by Ramot hereunder, and subject to the other terms of this
Agreement (including the remainder of this Article 4), Predix agrees to pay to
Ramot an annual minimum royalty of ten thousand dollars ($10,000), payable on
December 31, 2005, and on the each subsequent anniversary of that date during
the term of this Agreement.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       8
<PAGE>
All amounts paid by Predix under Section 4.4.1 shall be fully credited
against its obligations under this Section 4.4.2.

                  4.4.3 Maximum Annual Royalties. Anything herein to the
contrary notwithstanding, the maximum amount Predix shall be obligated to pay to
Ramot under Section 4.4.1 as royalties on Net Sales generated during any
calendar year shall be [*****************************].

            4.5 PAYMENT TERMS.

                  4.5.1 Payment. Predix shall make any payments under Section
4.4 to Ramot in arrears within [**************] from the end of each quarter in
which such payment accrues. Each royalty payment shall be accompanied by a
report for each country in the Territory in which sales of Licensed Products
occurred in the calendar quarter covered by such statement, specifying: the
gross sales and Net Sales in each country's currency; the applicable royalty
rate under this Agreement; the royalties payable in each country's currency,
including an accounting of deductions taken in the calculation of Net Sales; the
applicable exchange rate to convert from each country's currency to United
States Dollars under this Section 4.4; and the royalties payable in United
States Dollars. [***************************************************************
**********************************************].

                  4.5.2 Accounting. All payments hereunder shall be made in
United States dollars by wire transfer to a bank account designated by Ramot.
Conversion of foreign currency to United States dollars shall be made at the
conversion rate existing in the United States [*********************************
************************************************************************
**********************************************], then the rate of exchange to be
used shall be [****************************************************************]
as the Parties reasonably agree. Such payments shall be without deduction of
exchange, collection, or other charges.

                  4.5.3 Tax Withholding; Restrictions on Payment. All payments
hereunder shall be made free and clear of any taxes, duties, levies, fees or
charges, except for withholding taxes (to the extent applicable). If applicable
law requires that taxes be withheld from any amounts due Ramot under this
Agreement, Predix shall make any applicable withholding payments due on behalf
of Ramot and shall promptly provide Ramot with a statement including the amount
of tax withheld and justification therefore, and such other written
documentation regarding any such payment as available to Predix relating to an
application by Ramot for a foreign tax credit for such payment. If by law,
regulations or fiscal policy of a particular country in the Territory,
remittance of royalties in United States Dollars is restricted or forbidden,
written notice thereof shall promptly be given to Ramot, and payment of the
royalty shall be made by the deposit thereof in local currency to the credit of
Ramot in a recognized banking institution reasonably designated by Ramot by
written notice to Predix. Ramot shall be responsible for paying all income taxes
attributable to Ramot as a result of its receipt of funds hereunder, to the
extent applicable.

                  4.5.4 Late Payments. Any payments to be paid under this
Agreement that are not paid on or before the date such payments are due under
this Agreement [**************************************************************
**********************************************************************].

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       9
<PAGE>

            4.6 REPORTS; RECORDS RETENTION; REVIEW.

                  4.6.1 Reporting. Predix undertakes to notify Ramot promptly
following the grant of a Sublicense or the execution of an agreement for the
provision of Services. Each such notification shall include a brief summary of
the financial terms of such transaction.

                  4.6.2 Reports. In addition to the reports under Section 4.5.1,
commencing with the receipt of the first Sublicense Income or Service Income,
Predix shall provide Ramot with quarterly reports setting forth all Sublicense
Income and Service Income received by Predix and its Affiliates. In addition,
within [***********] after the end of each calendar year, Predix shall furnish
Ramot with a written report on the progress of its, its Affiliate's and
Sublicensees' efforts during the prior year to develop and commercialize
Licensed Products, including without limitation research and development
efforts, efforts to obtain Regulatory Approval and marketing efforts. All
reports provided by Predix under Section 4.6.1 and Section 4.6.2 shall
[********************************************************************].

                  4.6.3 Records. Commencing as of the date of the receipt of the
first Net Sales, Sublicense Income or Service Income hereunder, Predix and its
Affiliates shall keep for at least [***********] from the end of the calendar
year to which they pertain complete and accurate records of sales by Predix or
its Affiliates, as the case may be, of each Licensed Product and of Sublicense
Income and Service Income received, in sufficient detail to allow the accuracy
of the payments hereunder to be confirmed.

                  4.6.4 Review. Subject to the other terms of this Section
4.6.4, at the request of Ramot, which shall not be made more frequently than
[*****************] during the Term, upon reasonable prior notice from Ramot,
and at the expense of Ramot, except as otherwise provided herein, Predix and its
Affiliates shall permit an independent certified public accountant selected by
Ramot and reasonably acceptable to Predix to inspect, during regular business
hours, the relevant records required to be maintained by Predix and its
Affiliates under this Section 4.6. In every case the accountant must have
previously entered into a confidentiality agreement with both Parties
substantially similar to the provisions of Article 5 and limiting the disclosure
and use of such information by such accountant to authorized representatives of
the Parties and the purposes germane to this Section 4.6. Results of any such
review shall be binding on both Parties absent manifest error. Ramot agrees to
treat the results of any such accountant's review as Confidential Information of
Predix subject to the terms of Article 5. If any review reveals a deficiency in
the calculation and/or payment of royalties by Predix, then Predix shall
promptly pay Ramot the amount remaining to be paid, and if such underpayment is
by [*******************] of the amount payable during the period under audit,
Predix shall [**********************************************************] in
connection with the review.

      5. TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICATION

            5.1 Confidentiality. Commencing on the Effective Date and continuing
until the [*****************] of the expiration or earlier termination hereof,
each Party shall maintain in confidence the Confidential Information of the
other Party, shall not use or grant the use of the Confidential Information of
the other Party except as expressly permitted hereby, and

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       10
<PAGE>

shall not disclose the Confidential Information of the other Party except on a
need-to-know basis to such Party's directors, officers and employees, and to
such Party's consultants, to the extent such disclosure is necessary in
connection with such Party's activities as expressly authorized by this
Agreement. In addition to the foregoing, Predix may disclose Confidential
Information of Ramot to any Sublicensees that are bound by restrictions on
disclosure that are at least as stringent as those set forth herein. To the
extent that disclosure to any person is authorized by this Agreement, prior to
disclosure, a Party shall obtain, or shall have obtained prior to the date of
this Agreement, written agreement of such person pursuant to which such person
is bound to hold in confidence and not disclose, use or grant the use of the
Confidential Information of the other Party except as expressly permitted under
this Agreement. Each Party shall notify the other Party promptly upon discovery
of any unauthorized use or disclosure of the other Party's Confidential
Information.

            5.2 Terms of Agreement. Neither Party shall disclose any terms or
conditions of this Agreement to any Third Party without the prior consent of the
other Party; provided, however, that a Party may disclose the terms or
conditions of this Agreement: (a) on a need-to-know basis to its legal and
financial advisors to the extent such disclosure is reasonably necessary in
connection with such Party's activities as expressly permitted by this
Agreement, and (b) to a Third Party who is subject to confidentiality
obligations similar to those set forth herein in connection with: (i) an equity
investment in or by such Party, (ii) a merger, consolidation or similar
transaction involving such Party, (iii) the negotiation of a sublicense of
rights granted hereunder or (iv) the sale of all or substantially all of the
assets of such Party. Notwithstanding the foregoing, prior to execution of this
Agreement, the Parties have agreed upon the text of one or more press releases
that describe the terms and conditions of this transaction, and each Party may
disclose such information, as modified by mutual written agreement the Parties,
without the consent of the other Party.

            5.3 Permitted Disclosures. The confidentiality obligations under
this Article 5 shall not apply to the extent that a Party is required to
disclose information by applicable law, regulation or order of a governmental
agency or a court of competent jurisdiction; provided, however, that such Party
shall provide written notice thereof to the other Party, consult with the other
Party with respect to such disclosure and provide the other Party sufficient
opportunity to object to any such disclosure or to request confidential
treatment thereof.

      6. OWNERSHIP OF TECHNOLOGY AND INVENTIONS; FILING, PROSECUTION AND
MAINTENANCE OF PATENT RIGHTS

            6.1 OWNERSHIP OF TECHNOLOGY. Subject to the terms and conditions set
forth herein, including without limitation the license granted in Section 2.1,
Ramot shall own all right, title and interest in and to any and all Licensed
Technology. No rights or licenses in or to any Technology are conveyed hereunder
by implication or estoppel or by any means other than express grant.

            6.2 OWNERSHIP OF LICENSED PRODUCTS. Predix shall own all right,
title and interest in and to any and all Licensed Products, subject to Ramot's
ownership of the underlying Licensed Technology, the terms of the license
granted herein and Predix's obligations herein, including the obligation to pay
royalties as set forth above.

            6.3 PATENT FILING, PROSECUTION AND MAINTENANCE.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       11
<PAGE>

                  6.3.1 Licensed Patent Rights. Ramot and Predix shall consult
each other regarding the preparation, filing and prosecution of all patent
applications, and the maintenance of all patents, included within the Licensed
Patent Rights, including, without limitation, the content, timing and
jurisdiction of the filing of such patent applications and their prosecution,
and other details. Predix shall be responsible for preparing, filing,
prosecuting, obtaining and maintaining, at its sole cost and expense, using
patent counsel reasonably acceptable to Ramot, all Licensed Patent Rights, in
the name of Ramot, with the goal of obtaining and maintaining the Licensed
Patents in a manner that will provide the maximum economic advantage and return
to the Parties under this Agreement. Predix: (i) will provide Ramot with a copy
of any proposed patent application within such Licensed Patent Rights for review
and comment reasonably in advance of filing, and (ii) will keep Ramot informed
of the status of such filing, prosecution and maintenance, including, without
limitation, by providing Ramot with copies of all communications received from
or filed in patent office(s) with respect to such filing, and by providing
Ramot, a reasonable time prior to taking or failing to take any action that
would affect the scope or validity of any such filing (including the
substantially narrowing, cancellation or abandonment of any claim(s) without
retaining the right to pursue such subject matter in a separate application, or
the failure to file or perfect the filing of any claim(s) in any country), with
prior written notice of such proposed action or inaction so that Ramot has a
reasonable opportunity to review and comment. Predix shall not take any such
action that would affect the scope of validity or any such filing without the
prior written consent of Ramot. If Predix fails to undertake the filing(s),
prosecution, protection and/or maintenance of any patent application, patent or
submission within the Licensed Patent Rights, without the prior consent of
Ramot, all claims included in such patent applications, patents and/or
submissions shall be deemed Valid Claims within the Licensed Patent Rights for
purposes of Section 1.17 until such times as the relevant patents would have
expired had they continued to their fullest term.

                  6.3.2 Other Patent Rights. Except as set forth in Section
6.3.1, each Party shall be responsible for preparing, filing, prosecuting,
obtaining and maintaining, at its sole cost, expense and discretion, all of its
own Patent Rights. Predix undertakes to notify Ramot, on an annual basis, of the
filing by or on behalf of Predix or any of its AFFILIATES of any priority patent
application relating to or covering an actual or potential Licensed Product.
Each such notification shall include a brief summary of the invention disclosed
in such application.

            6.4 NOTICE OF INFRINGEMENT. If, during the Term, either Party learns
of any actual, alleged or threatened infringement by a Third Party of any
Licensed Patent Rights, such Party shall promptly notify the other Party and
shall provide such other Party with available evidence of such infringement.

            6.5 INFRINGEMENT OF PATENT RIGHTS. Predix, after consultation with
Ramot, shall have the first right, but not the obligation and with legal counsel
of its own choice, to bring suit, or take other appropriate legal action,
against any actual, alleged or threatened infringement of the Licensed Patent
Rights. If Ramot is joined as a party plaintiff in any such suit, Ramot shall
have the right to approve or disapprove of the counsel selected by Predix to
represent Predix and Ramot, such approval not to be unreasonably withheld. The
expenses of such suit or suits that Predix elects to bring, including any
expenses of Ramot incurred in conjunction with the prosecution of such suits or
the settlement thereof, shall be paid for entirely by Predix and Predix shall
hold Ramot free, clear and harmless from and against any and all costs of such
litigation, including attorney's fees. Predix shall not compromise or settle
such litigation without

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       12
<PAGE>

the prior written consent of Ramot, which consent shall not be unreasonably
withheld or delayed. Ramot shall have the right, at its own expense, to be
represented in any such action by Predix by counsel of Ramot's own choice. If
Predix does not file any action or proceeding against any such infringement
within three (3) months after the earlier of: (i) Predix's notice to Ramot under
Section 6.4 above, (ii) Ramot's notice to Predix under Section 6.2 above, or
(iii) a written request from Ramot to take action with respect to such
infringement, then Ramot shall have the right, but not the obligation, at its
own expense, to bring suit, or take other appropriate legal action, against such
actual, alleged or threatened infringement, with legal counsel of its own
choice, but shall not be permitted to settle any such suit without the prior
consent of Predix, which consent shall not be unreasonably withheld. Any
damages, monetary awards or other amounts recovered, whether by judgment or
settlement, pursuant to any suit, proceeding or other legal action taken under
this Section 6.3, shall be applied as follows:

                  (a) First, to reimburse the Parties for their respective costs
and expenses (including reasonable attorneys' fees and costs) incurred in
prosecuting such enforcement action; and

                  (b) Second, any amounts remaining shall be allocated as
follows: (a) if Ramot is the Party bringing such suit or proceeding or taking
such other legal action, [********************************], (b) if Predix is
the Party bringing such suit or proceeding or taking such other legal action,
[****************************], and (c) if the suit is brought jointly,
[*************************].

If a Party brings any such action or proceeding hereunder, the other Party
agrees to be joined as Party plaintiff if necessary to prosecute such action or
proceeding, and to give the Party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; provided, however, that
neither Party shall be required to transfer any right, title or interest in or
to any property to the other Party or any Third Party to confer standing on a
Party hereunder.

      7. REPRESENTATIONS AND WARRANTIES

            7.1 RAMOT REPRESENTATIONS. Ramot represents and warrants to Predix
that:

            (a) the execution and delivery of this Agreement and the performance
of the transactions contemplated hereby have been duly authorized by all
appropriate Ramot corporate action;

            (b) this Agreement is a legal and valid obligation binding upon
Ramot and enforceable in accordance with its terms, and the execution, delivery
and performance of this Agreement by the Parties does not conflict with any
agreement, instrument or understanding to which Ramot is a Party or by which it
is bound;

            (c) Ramot has the full right and legal capacity to grant the rights
granted to Predix hereunder;

            (d) To the best of Ramot's knowledge, the Licensed Patent Rights
have been properly filed and prosecuted and Ramot is the sole owner of the
Licensed Patent Rights;

            (e) Ramot has no actual knowledge as of the date hereof of any legal
suit or proceeding by a third party (whether threatened or filed) against Ramot
or TAU contesting the

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       13
<PAGE>

ownership or validity of the Licensed Patent Rights, or claiming that the
practice of the Licensed Patent Rights in the manner contemplated by this
Agreement would infringe the rights of such third party;

            (f) Ramot will not grant or convey any rights or licenses to the
Licensed Technology that may limit Predix's ability to exercise the rights and
licenses granted herein to their fullest extent; and

            (g) No member of Ramot's legal staff has received notice of any
infringement or misappropriation by a Third Party of the Licensed Technology.

            7.2 PREDIX REPRESENTATIONS. Predix represents and warrants to Ramot
      that:

            (a) the execution and delivery of this Agreement and the performance
of the transactions contemplated hereby have been duly authorized by all
appropriate Predix corporate action; and

            (b) this Agreement is a legal and valid obligation binding upon
Predix and enforceable in accordance with its terms, and the execution, delivery
and performance of this Agreement by the Parties does not conflict with any
agreement, instrument or understanding to which Predix is a Party of or by which
it is bound.

            (c) Predix will comply with, and shall ensure that its Affiliates
and Sublicensees undertake to comply with, all local, state, federal, and
international laws and regulations relating to the use of the Licensed
Technology and the development, manufacture, use, license and sale of Licensed
Products.

            7.3 NO WARRANTIES.

                  7.3.1 Nothing in this Agreement is or shall be construed as:

                        (a) a warranty or representation by either Party as to
the validity or scope of any patent application or patent licensed hereunder;

                        (b) a warranty or representation that the Licensed
Technology or anything made, used, sold or otherwise disposed of under any
license granted pursuant to this Agreement is or will be free from infringement
of patents, copyrights, and other rights of third Parties.

                  7.3.2 Except as expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF
ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER
EXPRESS OR IMPLIED WARRANTIES.

      8. INDEMNIFICATION; INSURANCE

            8.1 INDEMNIFICATION. Predix shall indemnify, defend and hold
harmless Ramot, its Affiliates and their respective governors, directors,
officers, employees, stockholders

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       14
<PAGE>

and agents and their respective successors, heirs and assigns (the "Ramot
Indemnitees") from and against any liability, damage, loss or expense (including
reasonable attorneys' fees and expenses of litigation) incurred by or imposed
upon such Ramot Indemnitees, or any of them, in connection with any Third Party
claims, suits, actions, demands or judgments, including, without limitation,
personal injury and product liability matters, to the extent arising out of: (a)
the development, testing, production, manufacture, supply, promotion, import,
sale or use by any person of any Software Product or Licensed Product (or any
component thereof) manufactured or sold by Predix or any Affiliate or
Sublicensee under this Agreement, (b) the use of the Licensed Technology or
practice of the Licensed Patent Rights by Predix, any of its Affiliates or any
Sublicensees, (c) any material breach of this Agreement by Predix, (d) any
breach by a Sublicensee of a Sublicense, or (e) the gross negligence or willful
misconduct on the part of Predix or any Affiliate or Sublicensee, in any such
case under this Section 8.1.1, except to the extent any of the foregoing is
caused by the negligence or willful misconduct of Ramot or a breach of this
Agreement by Ramot.

            8.2 INDEMNIFICATION PROCEDURES. In the event that any Indemnitee is
seeking indemnification under Section 8.1 above from Predix, Ramot shall notify
Predix of such claim with respect to such Indemnitee as soon as reasonably
practicable after the Ramot Indemnitee receives notice of the claim, and Ramot
(on behalf of itself and such Ramot Indemnitee) shall permit the Predix to
assume direction and control of the defense of the claim (including the right to
settle the claim solely for monetary consideration, provided that no settlement
shall be made without the consent of Ramot, which consent shall not be
unreasonably withheld) and shall cooperate as requested (at the expense of
Predix) in the defense of the claim. The indemnification obligations under
Article 8 shall not apply to any harm suffered as a direct result of any delay
in notice to Predix hereunder or to amounts paid in settlement of any claim,
demand, action or other proceeding if such settlement is effected without the
consent of Predix, which consent shall not be withheld or delayed unreasonably.
The Indemnitee, its employees and agents, shall reasonably cooperate with Predix
and its legal representatives in the investigation of any claim, demand, action
or other proceeding covered by Section 8.1.

            8.3 INSURANCE. Predix shall, at its sole cost and expense, procure
and maintain product liability insurance with respect to Licensed Products
commencing upon the First Commercial Sale of the first Licensed Product and
continuing until the termination of this Agreement. Such insurance coverage
shall be on terms that are in keeping with industry standards within the
bio-pharmaceutical industry. The insurance shall be underwritten by a reputable
insurance carrier. Ramot shall be named as an additional insured on such policy
and shall be entitled to advance notice of cancellation or expiration of such
policy. Predix shall comply with the requirements and restrictions imposed by
such insurance policy including with respect to the full and timely payment of
all premiums due thereon. Predix shall provide a copy of such insurance policy
to Ramot upon request.

      9. TERM AND TERMINATION

            9.1 TERM; EXPIRATION. The term of this Agreement shall, unless
sooner terminated in accordance with this Section 9, expire upon the expiration
of the final payment obligation under Article 4 above (the "Term"). Upon the
expiration of the Term of this Agreement, Predix shall have a fully paid-up,
irrevocable, freely transferable and sublicensable exclusive license in the
Territory under the Licensed Patent Rights and Licensed Technology, to Develop,
have Developed, make, have made, use, have used, sell, offer for sale, have
sold,

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       15
<PAGE>

import and have imported any and all Licensed Products in the Territory for any
and all uses within the Field.

            9.2 TERMINATION RIGHTS FOR BREACH.

                  Subject to the other terms of this Agreement, this Agreement
and the rights and options granted herein may be terminated by either Party upon
any material breach by the other Party of any material obligation or condition,
effective thirty (30) days after giving written notice to the breaching Party of
such termination in the case of a payment breach and ninety (90) days after
giving written notice to the breaching Party of such termination in the case of
any other breach, which notice shall describe such breach in reasonable detail.
The foregoing notwithstanding, if such default or breach is cured or remedied or
shown to be non-existent within the aforesaid thirty (30) or ninety (90) day
period, the notice shall be automatically withdrawn and of no effect. However,
prior to giving any notice of termination for breach, the Parties shall first
attempt to resolve any disputes as to the existence of any breach as set forth
in Article 10.

            9.3 TERMINATION FOR BANKRUPTCY. In the event that either Party files
for protection under bankruptcy laws, makes an assignment for the benefit of
creditors, appoints or suffers appointment of a receiver or trustee over its
property, files a petition under any bankruptcy or insolvency act or has any
such petition filed against it which is not discharged within sixty (60) days of
the filing thereof, then the other Party may terminate this Agreement effective
immediately upon written notice to such Party.

            9.4 EFFECTS OF TERMINATION.

                  9.4.1 Termination for Predix Breach. Upon any termination of
this Agreement by Ramot under Section 9.2, as of the effective date of such
termination all relevant licenses and sublicenses granted by Ramot to Predix
hereunder shall terminate automatically. Notwithstanding the foregoing: (a) no
such termination of this Agreement shall be construed as a termination of any
valid sublicense of any Sublicensee hereunder, and thereafter each such
Sublicensee shall be considered a direct licensee of Ramot, provided that (i)
such Sublicensee is then in full compliance with all terms and conditions of its
sublicense, (ii) all accrued payments obligations to Ramot have been paid, and
(iii) such Sublicensee agrees in writing to assume all applicable obligations of
Predix under this Agreement, and (b) Predix and its Affiliates and Sublicensees
shall have the right, for [**********] or such longer time period (if any) on
which the Parties mutually agree in writing, to sell or otherwise dispose of all
Licensed Products then on hand, with royalties to be paid to Ramot on all Net
Sales of such Licensed Products as provided for in this Agreement.

                  9.4.2 Termination for Ramot Breach. Upon any termination of
this Agreement by Predix under Section 9.2, as of the effective date of such
termination, Predix thereafter automatically shall have a fully sublicensable
and transferable, fully paid up (subject to the remainder of this Section 9.4),
exclusive license in the Territory under the Licensed Patent Rights and Licensed
Technology, to Develop, have Developed, make, have made, use, have used, sell,
offer for sale, have sold, import and have imported any and all Licensed
Products in the Territory for any and all uses within the Field, provided that
Predix shall pay, [***************************************************
********************************************************************************
********************************************************************************

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       16
<PAGE>

********] that would otherwise apply with respect to Net Sales, Sublicense
Income and Service Income under Section 4 of this Agreement.

            9.5 REMEDIES. Except as otherwise expressly set forth in this
Agreement, the termination provisions of this Article 9 are in addition to any
other relief and remedies available to either Party at law.

            9.6 SURVIVING PROVISIONS. Notwithstanding any provision herein to
the contrary, the rights and obligations of the Parties set forth in Articles 5,
7, 8 and 10 and Sections 6.1, 6.2, 9.1, 9.4, 9.5, 9.6, 11.1, 11.8, and 11.11 as
well as any rights or obligations otherwise accrued hereunder (including any
accrued payment obligations), shall survive the expiration or termination of the
Term.

      10. DISPUTE RESOLUTIONS

      10.1 DISPUTE RESOLUTION. Prior to engaging in any formal dispute
resolution with respect to any dispute, controversy or claim arising out of or
in relation to this Agreement, or the breach, termination or invalidity hereof
(each, a "Dispute"), the Chief Executive Officers of the Parties shall attempt
over a period of not less than [***********] to resolve such Dispute.

      11. MISCELLANEOUS

      11.1 GOVERNING LAW. Except as otherwise provided herein, this Agreement
shall be governed by, interpreted and construed in accordance with the laws of
the State of Israel, without regard to the conflicts of law principles thereof,
and sole jurisdiction is granted to the competent courts in Tel Aviv, Israel.

      11.2 WAIVER. No waiver by a Party hereto of any breach or default of any
of the covenants or agreements herein set forth shall be effective unless set
forth in a writing signed by the waiving Party or shall be deemed a waiver as to
any subsequent and/or similar breach or default.

      11.3 ASSIGNMENT. Neither this Agreement nor any right or obligation
hereunder may be assigned or delegated, in whole or part, by either Party
without the prior express written consent of the other; provided, however, that
either Party may, without the written consent of the other, assign this
Agreement and its rights and delegate its obligations hereunder in connection
with the transfer or sale of all or substantially all of its business, or in the
event of its merger, consolidation, change in control or similar transaction.
Any permitted assignee shall assume all obligations of its assignor under this
Agreement. Any purported assignment in violation of this Section 11.3 shall be
void.

      11.4 INDEPENDENT CONTRACTORS. The relationship of the Parties hereto is
that of independent contractors. Neither Party hereto shall be deemed to be the
agent, partner or joint venturer of the other for any purpose as a result of
this Agreement or the transactions contemplated thereby.

      11.5 FURTHER ACTIONS. Each Party agrees to execute, acknowledge and
deliver such further documents and instruments and to perform all such other
acts as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       17
<PAGE>

      11.6 NOTICES. All requests and notices required or permitted to be given
to the Parties hereto shall be given in writing, shall expressly reference the
section(s) of this Agreement to which they pertain, and shall be delivered to
the other Party, effective on receipt, at the appropriate address as set forth
below or to such other addresses as may be designated in writing by the Parties
from time to time during the term of this Agreement.

           If to Ramot:

                  Ramot at Tel Aviv University Ltd.
                  32 Haim Levanon Street
                  POB 39296
                  Tel Aviv 61392
                  ISRAEL

                  Attn: CEO

           If to Predix:

                  Predix Pharmaceuticals
                  10K Gill Street
                  Woburn, MA 01801
                  USA
                  Attn: Chief Executive Officer

                  Copy to:

                  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC
                  One Financial Center
                  Boston, MA 02111
                  USA
                  Attn: Christopher J. Denn, Esq.

      11.7 FORCE MAJEURE. Nonperformance of a Party (other than for the payment
of money) shall be excused to the extent that performance is rendered impossible
by strike, fire, earthquake, flood, governmental acts or orders or restrictions,
failure of suppliers, or any other reason where failure to perform is beyond the
reasonable control and not caused by the negligence, intentional conduct or
misconduct of the nonperforming Party; provided, however, that the nonperforming
Party shall use commercially reasonable efforts to resume performance as soon as
reasonably practicable.

      11.8 NO CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL A PARTY BE LIABLE FOR
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR
THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS
ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY
NOTICE OF SUCH DAMAGES.

      11.9 COMPLETE AGREEMENT. This Agreement constitutes the entire agreement
between the Parties regarding the subject matter hereof, and all prior
representations, understandings and agreements regarding the subject matter
hereof, either written or oral, expressed or implied, are

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       18
<PAGE>

superseded and shall be and of no effect.

      11.10 HEADINGS. The captions to the several sections hereof are not a part
of this Agreement, but are included merely for convenience of reference only and
shall not affect its meaning or interpretation.

      11.11 SECTION 365(n). All licenses granted under this Agreement are deemed
to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of
right to "intellectual property" as defined in Section 101 of such Code.

      11.12 FURTHER ASSURANCES. Each Party agrees to execute, acknowledge and
deliver such further instructions, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

      11.13 COUNTERPARTS. This Agreement may be executed simultaneously in one
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

      11.14 TERMINATION OF ORIGINAL AGREEMENT. The Parties acknowledge and agree
that: (i) the Original Agreement is hereby terminated as of the Restated
Effective Date and (ii) except as provided herein, all rights, obligations and
licenses provided for under the Original Agreement shall terminate and shall be
of no further force or effect on and after the Restated Effective Date.

                  [Remainder of page intentionally left blank]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       19
<PAGE>
      IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representative in two (2) originals.

<Table>
<Caption>
<S>                                                            <C>
PREDIX PHARMACEUTICALS
HOLDINGS, INC.                                                 RAMOT AT TEL AVIV UNIVERSITY LTD.

By: /s/ MICHAEL G. KAUFFMAN       /s/ CHEN SCHOR               By: /s/ ISAAC T. KOHLBERG       /s/ MENASHE KAY
    -------------------------------------------                    --------------------------------------------

Name: Michael Kauffman            Chen Schor                   Name: Isaac T. Kohlberg         Menashe Kay

Title: President and CEO CBO                                   Title: Chief Executive Officer Chief
                                                                      Operating Officer
</Table>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.

                                       20
<PAGE>

                                   EXHIBIT 1.6

                                DERIVED PRODUCTS

<TABLE>
<CAPTION>
PREDIX COMPOUNDS TARGET MINTZ LEVIN DOCKET NO. COUNTRY TITLE NAMED INVENTOR(S) APPLICATION NO. PATENT NO. FILING DATE
<S>              <C>                           <C>     <C>   <C>               <C>             <C>        <C>
[ * * * * * * * Exhibit 1.6 contains confidential material and has been omitted
                      in its entirety. * * * * * * * * * *]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [*] DENOTES
OMISSIONS.<PAGE>
                                                                   Exhibit 10.22

                      PREDIX PHARMACEUTICALS HOLDINGS, INC.

                        2005 EMPLOYEE STOCK PURCHASE PLAN

     The following constitute the provisions of the 2005 Employee Stock Purchase
Plan (the "Plan") of Predix Pharmaceuticals Holdings, Inc. (the "Company").

     1. Purpose. The purpose of the Plan is to provide Employees of the Company
and its Designated Subsidiaries with an opportunity to purchase Common Stock of
the Company. It is the intention of the Company to have the Plan qualify as an
"Employee Stock Purchase Plan" under Section 423 of the Code. The provisions of
the Plan shall, accordingly, be construed so as to extend and limit
participation in a manner consistent with the requirements of that section of
the Code.

     2. Definitions.

     (a) "Board" shall mean the Board of Directors of the Company, or a
committee of the Board of Directors named by the Board to administer the Plan.

     (b) "Code" shall mean the Internal Revenue Code of 1986, as amended.

     (c) "Common Stock" shall mean the common stock, $0.01 par value, of the
Company.

     (d) "Company" shall mean Predix Pharmaceuticals Holdings, Inc., a Delaware
corporation.

     (e) "Compensation" shall mean all compensation that is taxable income for
federal income tax purposes, including, payments for overtime, shift premium,
incentive compensation, incentive payments, bonuses, commissions and other
compensation received from the Company or a Designated Subsidiary, but excludes
relocation, expense reimbursements, tuition or other reimbursements and income
realized as a result of participation in any stock option, stock purchase or
similar plan of the Company or a Designated Subsidiary.

     (f) "Continuous Status as an Employee" shall mean the absence of any
interruption or termination of service as an Employee. Continuous Status as an
Employee shall not be considered interrupted in the case of a leave of absence
agreed to in writing by the Company, provided that such leave is for a period of
not more than 90 days or reemployment upon the expiration of such leave is
guaranteed by contract or statute.

     (g) "Contributions" shall mean all amounts credited to the account of a
participant pursuant to the Plan.

     (h) "Designated Subsidiaries" shall mean the Subsidiaries which have been
designated by the Board from time to time in its sole discretion as eligible to
participate in the Plan.

     (i) "Employee" shall mean any person who is employed by the Company or one
of its Designated Subsidiaries for tax purposes and who is customarily employed
for at least 20 hours per week and more than five months in a calendar year by
the Company or one of its Designated Subsidiaries.

     (j) "Exercise Date" shall mean the last business day of each Offering
Period of the Plan.
<PAGE>
     (k) "Exercise Price" shall mean with respect to an Offering Period, an
amount equal to 85% of the Fair Market Value (as defined in paragraph 7(b)) of a
share of Common Stock on the Offering Date or on the Exercise Date, whichever is
lower.

     (l) "Offering Date" shall mean the first business day of each Offering
Period of the Plan.

     (m) "Offering Period" shall mean a period of six months commencing on
January 1 and July 1 of each calendar year other than the Initial Offering
Period as set forth in paragraph 4.

     (n) "Plan" shall mean this Predix Pharmaceuticals Holdings, Inc. 2005
Employee Stock Purchase Plan.

     (o) "Subsidiary" shall mean a corporation, domestic or foreign, of which
not less than 50% of the voting shares are held by the Company or a Subsidiary,
whether or not such corporation now exists or is hereafter organized or acquired
by the Company or a Subsidiary.

     3. Eligibility.

     (a) Except as otherwise determined by the Board, any person who has been
continuously employed as an Employee on December 15th for an Offering Period
commencing on or about January 1 and on June 15th for an Offering Period
commencing on or about July 1 shall be eligible to participate in such Offering
Period under the Plan and further, subject to the requirements of paragraph 5(a)
and the limitations imposed by Section 423(b) of the Code.

     (b) Any provisions of the Plan to the contrary notwithstanding, no Employee
shall be granted an option under the Plan (i) if, immediately after the grant,
such Employee (or any other person whose stock would be attributed to such
Employee pursuant to Section 424(d) of the Code) would own stock and/or hold
outstanding options to purchase stock possessing five percent (5%) or more of
the total combined voting power or value of all classes of stock of the Company
or of any Subsidiary of the Company, or (ii) which permits his or her rights to
purchase stock under all employee stock purchase plans (described in Section 423
of the Code) of the Company and its Subsidiaries to accrue at a rate which
exceeds $25,000 of fair market value of such stock as defined in paragraph 7(b)
(determined at the time such option is granted) for each calendar year in which
such option is outstanding at any time. Any option granted under the Plan shall
be deemed to be modified to the extent necessary to satisfy this paragraph 3(b).

     4. Offering Periods. The Plan shall be implemented by a series of Offering
Periods, with a new Offering Period commencing on January 1 and July 1 of each
year or the first business day thereafter (or at such other time or times as may
be determined by the Board). The initial Offering Period shall commence on the
first business day following January 1, 2006 unless otherwise determined by the
Board (the "Initial Offering Period").

                                        2
<PAGE>
     5. Participation.

     (a) An eligible Employee may become a participant in the Plan by completing
an Enrollment Form provided by the Company and filing it with the Company or its
designee on or before December 15th for an Offering Period commencing on or
about January 1 and June 15th for an Offering Period commencing on or about July
1, unless a later time for filing the Enrollment Form is set by the Board for
all eligible Employees with respect to a given Offering Period. The Enrollment
Form and its submission may be electronic as directed by the Company. The
Enrollment Form shall set forth the percentage of the participant's Compensation
(which shall be not less than 1% and not more than 10%) to be paid as
Contributions pursuant to the Plan.

     (b) Payroll deductions shall commence with the first payroll following the
Offering Date, unless a later time is set by the Board with respect to a given
Offering Period, and shall end on the last payroll paid on or prior to the
Exercise Date of the Offering Period to which the Enrollment Form is applicable,
unless sooner terminated as provided in paragraph 10.

     6. Method of Payment of Contributions.

     (a) Each participant shall elect to have payroll deductions made on each
payroll during the Offering Period in an amount not less than 1% and not more
than 10% of such participant's Compensation on each such payroll; provided that
the aggregate of such payroll deductions during the Offering Period shall not
exceed 10% of the participant's aggregate Compensation during said Offering
Period (or such other percentage as the Board may establish from time to time
before an Offering Date). All payroll deductions made by a participant shall be
credited to his or her account under the Plan. A participant may not make any
additional payments into such account.

     (b) A participant may discontinue his or her participation in the Plan as
provided in paragraph 10, or, on one occasion only during the Offering Period,
may decrease, but may not increase, the rate of his or her Contributions during
the Offering Period by completing and filing with the Company a new Enrollment
Form authorizing a change in the deduction rate. The change in rate shall be
effective as of the beginning of the next payroll period following the date of
filing of the new Enrollment Form, if the Enrollment Form is completed at least
ten business days prior to such date, and, if not, as of the beginning of the
next succeeding payroll period.

     (c) Notwithstanding the foregoing, to the extent necessary to comply with
Section 423(b)(8) of the Code and paragraph 3(b), a participant's payroll
deductions may be decreased to zero at such time and for so long as the
aggregate of all payroll deductions accumulated with respect to the current
Offering Period and any other Offering Period ending within the current calendar
year equals $21,250. Payroll deductions shall recommence at the rate provided in
such participant's Enrollment Form at the beginning of the first Offering Period
which is scheduled to end in the following calendar year, unless terminated by
the participant as provided in paragraph 10.

     7. Grant of Option.

     (a) On the Offering Date of each Offering Period, each eligible Employee
participating in such Offering Period shall be granted an option to purchase on
the Exercise Date of such Offering Period a number of shares of the Common Stock
determined by dividing such Employee's Contributions accumulated prior to such
Exercise Date and retained in the participant's account as of the Exercise Date
by the applicable Exercise Price; provided however, that such purchase shall be
subject to the limitations set forth in paragraphs 3(b) and 12. The fair market
value of a share of the Common Stock shall be determined as provided in
paragraph 7(b).

                                        3
<PAGE>
     (b) The fair market value of the Common Stock on a given date shall be
determined by the Board based on (i) if the Common Stock is listed on a national
securities exchange or traded in the over-the-counter market and sales prices
are regularly reported for the Common Stock, the closing or last sale price of
the Common Stock for such date (or, in the event that the Common Stock is not
traded on such date, on the immediately preceding trading date), on the
composite tape or other comparable reporting system or (ii) if the Common Stock
is not listed on a national securities exchange and such price is not regularly
reported, the mean between the bid and asked prices per share of the Common
Stock at the close of trading in the over-the-counter market.

     8. Exercise of Option. Unless a participant withdraws from the Plan as
provided in paragraph 10, his or her option for the purchase of shares will be
exercised automatically on the Exercise Date of the Offering Period, and the
maximum number of full shares subject to the option will be purchased for him or
her at the applicable Exercise Price with the accumulated Contributions in his
or her account. If a fractional number of shares results, then such number shall
be rounded down to the next whole number and any unapplied cash shall be carried
forward to the next Exercise Date, unless the participant requests a cash
payment. The shares purchased upon exercise of an option hereunder shall be
deemed to be transferred to the participant on the Exercise Date. During a
participant's lifetime, a participant's option to purchase shares hereunder is
exercisable only by him or her.

     9. Delivery. Upon the written request of a participant, certificates
representing the shares purchased upon exercise of an option will be issued as
promptly as practicable after the Exercise Date of each Offering Period to
participants who wish to hold their shares in certificate form.

     10. Withdrawal; Termination of Employment.

     (a) A participant may withdraw all but not less than all the Contributions
credited to his or her account under the Plan at any time prior to the Exercise
Date of the Offering Period by giving written notice to the Company or its
designee. All of the participant's Contributions credited to his or her account
will be paid to him or her promptly after receipt of his or her notice of
withdrawal and his or her option for the current period will be automatically
terminated, and no further Contributions for the purchase of shares will be made
during the Offering Period.

     (b) Upon termination of the participant's Continuous Status as an Employee
prior to the Exercise Date of the Offering Period for any reason, including
retirement or death, the Contributions credited to his or her account will be
returned to him or her or, in the case of his or her death, to the person or
persons entitled thereto under paragraph 14, and his or her option will be
automatically terminated.

     (c) In the event an Employee fails to remain in Continuous Status as an
Employee for at least 20 hours per week during the Offering Period in which the
Employee is a participant, he or she will be deemed to have elected to withdraw
from the Plan and the Contributions credited to his or her account will be
returned to him or her and his or her option terminated.

     (d) A participant's withdrawal from an Offering Period will not have any
effect upon his or her eligibility to participate in a succeeding offering or in
any similar plan which may hereafter be adopted by the Company.

     11. Interest. No interest shall accrue on the Contributions of a
participant in the Plan.

                                        4
<PAGE>
     12. Stock.

     (a) The maximum number of shares of Common Stock which shall be made
available for sale under the Plan shall be 350,000 shares (this number reflects
the 1-for-18 reverse stock split effected in October, 2005), plus an increase
on the first day of each fiscal year every third year commencing on January 1,
2009, equal to the lesser of (i) 500,000 shares, (ii) one percent of the shares
of Common Stock outstanding on the last day of the immediately preceding fiscal
year, or (iii) such lesser number of shares as is determined by the Board,
subject to adjustment upon changes in capitalization of the Company as provided
in paragraph 18. If the total number of shares which would otherwise be subject
to options granted pursuant to paragraph 7(a) on the Offering Date of an
Offering Period exceeds the number of shares then available under the Plan
(after deduction of all shares for which options have been exercised), the
Company shall make a pro rata allocation of the shares remaining available for
option grants in as uniform a manner as shall be practicable and as it shall
determine to be equitable. Any amounts remaining in an Employee's account not
applied to the purchase of shares pursuant to this paragraph 12 shall be
refunded on or promptly after the Exercise Date. In such event, the Company
shall give written notice of such reduction of the number of shares subject to
the option to each Employee affected thereby and shall similarly reduce the rate
of Contributions, if necessary.

     (b) The participant will have no interest or voting right in shares covered
by his or her option until such option has been exercised.

     13. Administration. The Board shall supervise and administer the Plan and
shall have full power to adopt, amend and rescind any rules deemed desirable and
appropriate for the administration of the Plan and not inconsistent with the
Plan, to construe and interpret the Plan, and to make all other determinations
necessary or advisable for the administration of the Plan.

     14. Designation of Beneficiary.

     (a) A participant may designate a beneficiary who is to receive any shares
and cash, if any, from the participant's account under the Plan in the event of
such participant's death subsequent to the end of the Offering Period but prior
to delivery to him or her of such shares and cash. In addition, a participant
may designate a beneficiary who is to receive any cash from the participant's
account under the Plan in the event of such participant's death prior to the
Exercise Date of the Offering Period. If a participant is married and the
designated beneficiary is not the spouse, spousal consent shall be required for
such designation to be effective. Beneficiary designations shall be made either
in writing or by electronic delivery as directed by the Company.

     (b) Such designation of beneficiary may be changed by the participant (and
his or her spouse, if any) at any time by submission of the required notice,
which may be electronic. In the event of the death of a participant and in the
absence of a beneficiary validly designated under the Plan who is living at the
time of such participant's death, the Company shall deliver such shares and/or
cash to the executor or administrator of the estate of the participant, or if no
such executor or administrator has been appointed (to the knowledge of the
Company), the Company, in its discretion, may deliver such shares and/or cash to
the spouse or to any one or more dependents or relatives of the participant, or
if no spouse, dependent or relative is known to the Company, then to such other
person as the Company may designate.

     15. Transferability. Neither Contributions credited to a participant's
account nor any rights with regard to the exercise of an option or to receive
shares under the Plan may be assigned, transferred, pledged or otherwise
disposed of in any way (other than by will, the laws of descent and distribution
or as provided in paragraph 14) by the participant. Any such attempt at
assignment, transfer, pledge or other

                                        5
<PAGE>
disposition shall be without effect, except that the Company may treat such act
as an election to withdraw funds in accordance with paragraph 10.

     16. Use of Funds. All Contributions received or held by the Company under
the Plan may be used by the Company for any corporate purpose, and the Company
shall not be obligated to segregate such Contributions.

     17. Reports. Individual accounts will be maintained for each participant in
the Plan. Statements of account will be given to participating Employees
promptly following the Exercise Date, which statements will set forth the
amounts of Contributions, the per share purchase price, the number of shares
purchased and the remaining cash balance, if any.

     18. Adjustments Upon Changes in Capitalization. Subject to any required
action by the stockholders of the Company, the number of shares of Common Stock
covered by unexercised options under the Plan and the number of shares of Common
Stock which have been authorized for issuance under the Plan but are not yet
subject to options (collectively, the "Reserves"), the number of shares of
Common Stock set forth in paragraph 12(a)(i), as well as the price per share of
Common Stock covered by each unexercised option under the Plan, shall be
proportionately adjusted for any increase or decrease in the number of issued
shares of Common Stock resulting from a stock split, reverse stock split, stock
dividend, combination or reclassification of the Common Stock. Such adjustment
shall be made by the Board, whose determination in that respect shall be final,
binding and conclusive.

          In the event of the proposed dissolution or liquidation of the
Company, an Offering Period then in progress will terminate immediately prior to
the consummation of such proposed action, unless otherwise provided by the
Board. In the event of a proposed sale of all or substantially all of the assets
of the Company, or the merger, consolidation or other capital reorganization of
the Company with or into another corporation, each option outstanding under the
Plan shall be assumed or an equivalent option shall be substituted by such
successor corporation or a parent or subsidiary of such successor corporation,
unless the Board determines, in the exercise of its sole discretion and in lieu
of such assumption or substitution, to shorten the Offering Period then in
progress by setting a new Exercise Date (the "New Exercise Date"). If the Board
shortens the Offering Period then in progress in lieu of assumption or
substitution in the event of a merger or sale of assets, the Board shall notify
each participant in writing, at least ten days prior to the New Exercise Date,
that the Exercise Date for his or her option has been changed to the New
Exercise Date and that his or her option will be exercised automatically on the
New Exercise Date, unless prior to such date he or she has withdrawn from the
Offering Period as provided in paragraph 10. For purposes of this paragraph, an
option granted under the Plan shall be deemed to be assumed if, following the
sale of assets, merger or other reorganization, the option confers the right to
purchase, for each share of Common Stock subject to the option immediately prior
to the sale of assets, merger or other reorganization, the consideration
(whether stock, cash or other securities or property) received in the sale of
assets, merger or other reorganization by holders of Common Stock for each share
of Common Stock held on the effective date of such transaction (and if such
holders were offered a choice of consideration, the type of consideration chosen
by the holders of a majority of the outstanding shares of Common Stock);
provided, however, that if such consideration received in such transaction was
not solely common stock of the successor corporation or its parent (as defined
in Section 424(e) of the Code), the Board may, with the consent of the successor
corporation, provide for the consideration to be received upon exercise of the
option to be solely common stock of the successor corporation or its parent
equal in fair market value to the per share consideration received by holders of
Common Stock in the sale of assets, merger or other reorganization.

          The Board may, if it so determines in the exercise of its sole
discretion, also make provision for adjusting the Reserves, as well as the price
per share of Common Stock covered by each

                                        6
<PAGE>
outstanding option, in the event that the Company effects one or more
reorganizations, recapitalizations, rights offerings or other increases or
reductions of shares of its outstanding Common Stock, and in the event of the
Company being consolidated with or merged into any other corporation.

     19. Amendment or Termination.

          (a) The Board may at any time terminate or amend the Plan. Except as
provided in paragraph 18, no such termination may affect options previously
granted, nor may an amendment make any change in any option theretofore granted
which adversely affects the rights of any participant provided that an Offering
Period may be terminated by the Board on an Exercise Date or by the Board's
setting a new Exercise Date with respect to an Offering Period then in progress
if the Board determines that termination of the Offering Period is in the best
interests of the Company and the stockholders or if continuation of the Offering
Period would cause the Company to incur adverse accounting charges in the
generally-accepted accounting rules applicable to the Plan. In addition, to the
extent necessary to comply with Section 423 of the Code (or any successor rule
or provision or any applicable law or regulation), the Company shall obtain
stockholder approval in such a manner and to such a degree as so required.

          (b) Without stockholder consent and without regard to whether any
participant rights may be considered to have been adversely affected, the Board
shall be entitled to change the Offering Periods, limit the frequency and/or
number of changes in the amount withheld during an Offering Period, establish
the exchange ratio applicable to amounts withheld in a currency other than U.S.
dollars, permit payroll withholding in excess of the amount designated by a
participant in order to adjust for delays or mistakes in the Company's
processing of properly completed withholding elections, establish reasonable
waiting and adjustment periods and/or accounting and crediting procedures to
ensure that amounts applied toward the purchase of Common Stock for each
participant properly correspond with amounts withheld from the participant's
Compensation, and establish such other limitations or procedures as the Board
determines in its sole discretion advisable that are consistent with the Plan.

     20. Notices. All notices or other communications by a participant to the
Company under or in connection with the Plan shall be deemed to have been duly
given when received in the form specified by the Company at the location, or by
the person, designated by the Company for the receipt thereof.

     21. Conditions Upon Issuance of Shares. Shares shall not be issued with
respect to an option unless the exercise of such option and the issuance and
delivery of such shares pursuant thereto shall comply with all applicable
provisions of law, domestic or foreign, including, without limitation, the
Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as
amended, the rules and regulations promulgated thereunder, and the requirements
of any stock exchange upon which the shares may then be listed, and shall be
further subject to the approval of counsel for the Company with respect to such
compliance.

     As a condition to the exercise of an option, the Company may require the
person exercising such option to represent and warrant at the time of any such
exercise that the shares are being purchased only for investment and without any
present intention to sell or distribute such shares if, in the opinion of
counsel for the Company, such a representation is required by any of the
aforementioned applicable provisions of law.

     22. Right to Terminate Employment. Nothing in the Plan or in any agreement
entered into pursuant to the Plan shall confer upon any Employee or other
optionee the right to continue in the employment of the Company or any
Subsidiary, or affect any right which the Company or any Subsidiary may have to
terminate the employment of such Employee or other optionee.

                                        7
<PAGE>
     23. Rights as a Stockholder. Neither the granting of an option nor a
deduction from payroll shall constitute an Employee the owner of shares covered
by an option. No optionee shall have any right as a stockholder unless and until
an option has been exercised, and the shares underlying the option have been
registered in the Company's share register.

     24. Term of Plan. The Plan became effective upon its adoption by the Board
on September 22, 2005 and shall continue in effect until December 31, 2025
unless sooner terminated under paragraph 19.

     25. Applicable Law. This Plan shall be governed in accordance with the laws
of the State of Delaware, applied without giving effect to any conflict of law
principles.

                                        8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]